Secukinumab provides clinical benefit in phase 3 juvenile arthritis trialJune 15, 2021Psoriatic Arthritis
Tender joints in active PsA poorly reflect inflammation indicated by ultrasound and MRIJune 4, 2021Psoriatic Arthritis
PsA: Rates of hospitalized serious infections lower with ustekinumab vs. other biologicsJune 4, 2021Psoriatic Arthritis
PsA: Upadacitinib shows consistent efficacy and safety in patients with inadequate response to biologicsJune 4, 2021Psoriatic Arthritis
PsA: No substantial change in body composition with ustekinumab treatmentJune 4, 2021Psoriatic Arthritis
Secukinumab, a comprehensive biologic treatment for management of concomitant PsA and psoriasisJune 4, 2021Psoriatic Arthritis
Is fecal microbiota transplantation beneficial in active peripheral PsA?June 4, 2021Psoriatic Arthritis
Lower SARS-CoV-2 vaccine responses seen in patients with immune-mediated inflammatory diseasesMay 25, 2021Psoriatic Arthritis
